(Q35016173)

5 August 2017

1 reference

title

Inflammatory myopathies: how to treat the difficult cases (English)

1 reference

5 August 2017

Mastaglia FL

1

1 reference

5 August 2017

Zilko PJ

series ordinal

2

1 reference

5 August 2017

publication date

1 January 2003

1 reference

Journal of Clinical Neuroscience

5 August 2017

published in

1 reference

5 August 2017

volume

10

1 reference

5 August 2017

issue

1

1 reference

5 August 2017

page(s)

99-101

1 reference

Treatment of autoimmune inflammatory myopathies

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0967-5868%2802%2900271-0

7 January 2021

Idiopathic inflammatory myopathies: optimum immunosuppressive treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0967-5868%2802%2900271-0

7 January 2021

Inclusion body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS0967-5868%2802%2900271-0

7 January 2021

Inflammatory Myopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0967-5868%2802%2900271-0

7 January 2021

Prednisone and azathioprine for polymyositis: long-term followup.

1 reference

https://api.crossref.org/works/10.1016%2FS0967-5868%2802%2900271-0

7 January 2021

Frequency of relapses in patients with polymyositis and dermatomyositis.

1 reference

https://api.crossref.org/works/10.1016%2FS0967-5868%2802%2900271-0

7 January 2021

Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0967-5868%2802%2900271-0

7 January 2021

Induction of Interleukin 2 Messenger RNA Inhibited by Cyclosporin A

1 reference

https://api.crossref.org/works/10.1016%2FS0967-5868%2802%2900271-0

7 January 2021

Cyclosporin in juvenile dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0967-5868%2802%2900271-0

7 January 2021

Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0967-5868%2802%2900271-0

7 January 2021

Mycophenolate mofetil for myasthenia gravis: an open-label pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0967-5868%2802%2900271-0

7 January 2021

Tacrolimus in refractory polymyositis with interstitial lung disease

1 reference

https://api.crossref.org/works/10.1016%2FS0967-5868%2802%2900271-0

7 January 2021

Polymyositis: remarkable response to total body irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0967-5868%2802%2900271-0

7 January 2021

Total body irradiation and the course of polymyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0967-5868%2802%2900271-0

7 January 2021

Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS0967-5868%2802%2900271-0

7 January 2021

Steroid myopathy: incidence and detection in a population with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0967-5868%2802%2900271-0

7 January 2021

Anti-Jo-1 positive inclusion body myositis with a marked and sustained clinical improvement after oral prednisone

1 reference

https://api.crossref.org/works/10.1016%2FS0967-5868%2802%2900271-0

7 January 2021

The treatment of inclusion body myositis: a retrospective review and a randomized, prospective trial of immunosuppressive therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0967-5868%2802%2900271-0

7 January 2021

Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0967-5868%2802%2900271-0

7 January 2021

A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM.

1 reference

https://api.crossref.org/works/10.1016%2FS0967-5868%2802%2900271-0

7 January 2021

High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0967-5868%2802%2900271-0

7 January 2021

Safety and efficacy of strength training in patients with sporadic inclusion body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS0967-5868%2802%2900271-0

7 January 2021

10.1016/S0967-5868(02)00271-0

Identifiers

DOI

1 reference

5 August 2017

1 reference